The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
Abstract
Patients with high-grade subtypes of endometrial carcinoma (grade 3 endometrioid, serous, clear cell, or carcinosarcoma) have a relatively poor prognosis. The specific subtype may be used to guide patient management, but there is little information on the reproducibility of subtype diagnosis in cases of high-grade endometrial carcinoma. Fifty-six cases diagnosed as a high-grade subtype of endometrial carcinoma were identified from the pathology archives of Vancouver General Hospital. All slides for each case were reviewed independently by 3 pathologists, who diagnosed the specific tumor subtype(s) and assigned the percentage of each subtype for mixed tumors. Agreement between observers was categorized as follows: major disagreement: (A) no consensus for low-grade endometrioid versus high-grade carcinoma (any subtype), or (B) no consensus with respect to the predominant high-grade subtype present; minor disagreement: consensus was reached about the cell type of the predominant component of a mixed tumor, but there was disagreement about the subtype of the minor component. A tissue microarray was constructed from these cases and immunostained for p16, ER, PR, PTEN, and p53. In 35 of 56 (62.5%) cases, there was agreement between all 3 reviewers regarding the subtype diagnosis of the exclusive (in pure tumors) or predominant (in mixed tumors) high-grade component. Of these cases, there was a minor disagreement (ie, disagreement about the minor high-grade component subtype in a mixed tumor) in 4 cases (4/56, 7.1%). In 20 of 56 (35.8%) cases there was a major disagreement; in 17 (30.4%) of these cases there was no consensus about the major subtype diagnosis, whereas in 3 (5.4%) cases there was disagreement about whether a component of high-grade endometrial carcinoma was present. In the final case, all 3 reviewers diagnosed the case as low-grade endometrioid carcinoma, disagreeing with the original diagnosis of high-grade carcinoma. The most frequent areas of disagreement were serous versus clear cell (7 cases) and serous versus grade 3 endometrioid (6 cases). Immunostaining results using the 5-marker immunopanel were then used to adjudicate in the 6 cases in which there was disagreement between reviewers with respect to serous versus endometrioid carcinoma, and these supported a diagnosis of serous carcinoma in 4 of 6 cases and endometrioid carcinoma in 2 of 6 cases. Pairwise comparison between the reviewers for the 20 cases classified as showing major disagreement was as follows: reviewer 1 and reviewer 2 agreed in 5/20 cases, reviewer 1 and reviewer 3 agreed in 7/20 cases, and reviewer 2 and reviewer 3 agreed in 8/20 cases, indicating that disagreements were not because of a single reviewer holding outlier opinions. Diagnostic consensus among 3 reviewers about the exclusive or major subtype of high-grade endometrial carcinoma was reached in only 35/56 (62.5%) cases, and in 4 of these cases there was disagreement about the minor component present. This poor reproducibility did not reflect systematic bias on the part of any 1 reviewer. There is a need for molecular tools to aid in the accurate and reproducible diagnosis of high-grade endometrial carcinoma subtype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Wárlám-Rodenhuis, C. C., De Winter, K. A., Lutgens, L. C., van den Bergh, A. C., van de Steen-Banasik, E., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02139-5 · Cited by 1,773
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Hamilton, C. A., Cheung, M. K., Osann, K., Chen, L., Teng, N. N., Longacre, T. A., Powell, M. A., Hendrickson, M. R., Kapp, D. S., & Chan, J. K. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603012 · Cited by 644
Hammond, M. E. H., Hayes, D. F., Dowsett, M., et al. (2010) · PubMed Central · Cited by 541
Ambros, R. A., Sherman, M. E., Zahn, C. M., Bitterman, P., & Kurman, R. J. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90203-1 · Cited by 305
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Self-citationContemporary management of endometrial cancer
Wright, J. D., Medel, N. I. B., Sehouli, J., Fujiwara, K., & Herzog, T. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60442-5 · Cited by 270
Cited by
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., Anglesio, M., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 975
Self-citationA clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Self-citationLeón-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00549 · Cited by 855
Kommoss, S., McConechy, M. K., Kommoss, F., Leung, S., Bunz, A., Magrill, J., Britton, H., Kommoss, F., Grevenkamp, F., Karnezis, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 776
Self-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
Classification of endometrial carcinoma: more than two types
Murali, R., Soslow, R. A., & Weigelt, B. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70591-6 · Cited by 647
Self-citationCurrent recommendations and recent progress in endometrial cancer
Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 573
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Bosse, T., Nout, R. A., McAlpine, J. N., McConechy, M. K., Britton, H., Hussein, Y. R., Gonzalez, C., Ganesan, R., Steele, J. C., Harrison, B. T., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001020 · Cited by 341
Self-citationSoslow, R. A., Tornos, C., Park, K. J., Malpica, A., Matias-Guiu, X., Oliva, E., Parkash, V., Carlson, J., McCluggage, W. G., & Gilks, C. B. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000518 · Cited by 317
Self-citationIncorporation of molecular characteristics into endometrial cancer management
Vermij, L., Smit, V., Nout, R., & Bosse, T. (2020) · Histopathology · doi:10.1111/his.14015 · Cited by 291
Murali, R., Davidson, B., Fadare, O., Carlson, J. A., Crum, C. P., Gilks, C. B., Irving, J. A., Malpica, A., Matias-Guiu, X., McCluggage, W. G., et al. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000491 · Cited by 278
Self-citationThe Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women
Cote, M. L., Ruterbusch, J. J., Olson, S. H., Lu, K., & Ali-Fehmi, R. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0316 · Cited by 272
McAlpine, J., Leon‐Castillo, A., & Bosse, T. (2018) · The Journal of Pathology · doi:10.1002/path.5034 · Cited by 254
Metadata
- Authors
- Gilks, C. B., Oliva, E., & Soslow, R. A.
- Venue
- American Journal of Surgical Pathology
- Published
- 2013-06
- Volume
- 37
- Issue
- 6
- Pages
- 874-881
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2014726838
- Cited by
- 401
- References
- 24
- FWCI
- 21.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.